NCT01052935View on ClinicalTrials.gov

A Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

January 31, 2010

Study Completion Date

October 31, 2010

Conditions
Group B Streptococcus (GBS) Disease
Interventions
BIOLOGICAL

Group B streptococcus (GBS) vaccine

"No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P1 study."

Trial Locations (1)

Unknown

Institute for Pharmacokinetic and Analytical Studies, Via Mastri, 36

Sponsors

Lead Sponsor

Novartis

Collaborators (1)

Novartis Vaccines
All Listed Sponsors
collaborator

Novartis Vaccines

INDUSTRY

lead

Novartis

INDUSTRY

NCT01052935 - A Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS Vaccine | Biotech Hunter | Biotech Hunter